Here's Why Gilead Sciences (GILD) is a Strong Value Stock

According to Zacks, Gilead Sciences (GILD) is currently rated a #3 (Hold) with a VGM Score of A and a Value Style Score of B, indicating potential value. The company's HIV franchise, driven by Biktarvy, saw sales of $19.6 billion in 2024, an 8% year-over-year increase, and the consensus estimate for fiscal 2025 has increased by $0.04 to $7.91 per share following upward revisions by analysts.

Analysis

Gilead Sciences (GILD) presents a noteworthy profile for investors, characterized by strong performance in its core HIV franchise and favorable valuation metrics, despite a neutral Zacks #3 (Hold) rating. The company's HIV segment generated $19.6 billion in sales in 2024, an 8% year-over-year increase, largely driven by the flagship drug Biktarvy and ongoing efforts in innovative HIV prevention treatments. This operational strength is complemented by a Zacks VGM Score of A and a Value Style Score of B, underpinned by an attractive forward P/E ratio of 13.79. Furthermore, recent analyst activity signals positive sentiment, with four upward revisions to fiscal 2025 earnings estimates in the past 60 days, resulting in a $0.04 increase in the Zacks Consensus Estimate to $7.91 per share. GILD has also demonstrated a consistent ability to exceed earnings expectations, with an average earnings surprise of 16.5%, suggesting resilient operational execution and alignment with Zacks' assertion that GILD should be on investors' short lists.

Key Decisions for Investors

• Investors, particularly those with a value-oriented strategy, may find GILD worthy of further due diligence, considering its 'B' Value Score, 'A' VGM Score, and a forward P/E ratio of 13.79, despite the current Zacks #3 (Hold) rating.
• It is advisable to monitor upcoming earnings reports and further analyst estimate revisions for GILD, as sustained positive momentum in earnings expectations could indicate strengthening fundamentals and potentially precede an upgrade in its Zacks Rank.
• Investors should closely track the ongoing performance of Gilead's HIV franchise, specifically sales growth from Biktarvy and progress in the development pipeline for new HIV treatments, as this segment remains a critical driver of the company's revenue and growth.